Oncology clinical trials at Murdoch

The Murdoch Oncology Clinical Trial Unit was established in 2012, with the aim of providing West Australian oncology patients and their families the best possible care through research-driven practice. Our current portfolio of trials examine outcomes of conventional and innovative cancer treatments.

Clinical trials

R3767-ONC-2266

A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC

https://clinicaltrials.gov/study/NCT06161441

PI: A/Prof Kynan Feeney

Sponsor: Regeneron Pharmaceuticals

CA224-1093

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent NSQ NSCLC With PD-L1 1-49%

https://clinicaltrials.gov/study/NCT06561386

PI: A/Prof Kynan Feeney

Sponsor: Bristol-Myers Squibb

R3767-ONC-2236

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

https://clinicaltrials.gov/study/NCT05800015

PI: A/Prof Kynan Feeney

Sponsor: Regeneron Pharmaceuticals

SGNB6A-002

A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01)

https://clinicaltrials.gov/study/NCT06012435

PI: A/Prof Kynan Feeney

Sponsor: Seagen Inc

CA245-0001

BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer

PI: Dr Adeolu Freeman

Sponsor: Bristol-Myers Squibb

SAFFRON

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

https://clinicaltrials.gov/show/NCT05261399

PI: Dr Raj Tota

Sponsor: AstraZeneca

PRISM-1

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

https://clinicaltrials.gov/study/NCT06608927

PI: Dr Kynan Feeney

Sponsor: Arcus Biosciences, Inc.

GLORIA

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive Triple Negative Breast Cancer

https://clinicaltrials.gov/show/NCT03562637

PI: Dr Daphne Tsoi

Sponsor: OBI Pharma

FIERCE-HN

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma

https://clinicaltrials.gov/study/NCT06064877

PI: Dr Raj Tota

AVEO Pharmaceuticals, Inc

IOS-1002-201

A Phase 1a/1b first-in-human study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002 administered alone and in combination with pembrolizumab in advanced solid tumors.

PI: Dr Kynan Feeney

Sponsor: ImmunOs Therapeutics

Cancer is the leading cause of death in Australia, about one in two Australian men and one in three Australian women will be diagnosed with cancer by the age of 85.
Clinical trials play an essential role in discovering new and more effective treatments for cancer.
Great strides are being made in understanding cancer and we are working every day to achieve better quality and quantity of life for patients.

Providing exceptional care to patients by offering innovative cancer treatment which may only be available in a clinical trial setting.
Conducting clinical trials for patients having treatment for a range of cancer types including lung, breast, colorectal and upper gastrointestinal cancer.
Continual improvement of clinical trial processes and alignment with contemporary best practice.

Associate Professor Kynan Feeney - Medical Oncologist
Associate Professor Daphne Tsoi - Medical Oncologist
Dr Sanjay Mukhedkar - Medical Oncologist
Dr Raj Tota – Medical Oncologist
Dr Tim Slattery - Medical Oncologist
Dr Adeolu Freeman - Medical Oncologist
Rebecca Weselman – Clinical Trials Regulatory & Quality Officer
Sabina Jelinek - Clinical Trials Nurse
Tijana Coe – Senior Clinical Trial Co-ordinator
Diane DeVilla – Senior Clinical Trial Co-ordinator
Uzoamaka Samuel-Oparah - Clinical Trial Co-ordinator
Mel Hernandez - Clinical Trial Co-ordinator
Tina Kern – Clinical Trials Support Officer
Sean Tee - Clinical Trials Pharmacist

Yap N, Wong V, Morton C, de Boer R, Baron-Hay S, Tsoi D, et al. (2024) Medicine Access Programmes: what do patients think – a patient‐reported outcome study on ribociclib in metastatic breast cancer in Australia. Internal Medicine Journal 54 DOI: 10.1111/imj.16536
Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K et al. (2024) First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. Journal of Clinical Oncology 42 DOI: 10.1200/JCO.23.01636
Cho BC, Lu S, Felip E, Spira AI, Girard N, Mukhedkar S et al (2024) Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. New England Journal of Medicine 391:1486-1498. DOI: 10.1056/NEJMoa2403614
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Feeney K et al (2024) First-line Nivolumab Plus chemotherapy for advanced Gastric, Gastroesophageal Junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. Journal of Clinical Oncology 42 DOI: 10.1200/JCO.23.01601
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, et al. (2022) Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. Mar 23. DOI: 10.1038/s41586-022-04508-4.
Paz-Ares LG, Ciuleanu TE, Cobo-Dols M, Bennouna J, Cheng Y, Mizutani H, Lingua A, Reyes F, Reinmuth N, De Menezes JJ, Jassem J, Protsenko S, Feeney K, et al. (2022) First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. Journal of Clinical Oncology 40 Suppl 17. DOI:10.1200/JCO.2022.40.17_suppl.LBA9026.
Chan A, Lomma C, Chih H, Blackely E, Woodward N, Tsoi D, et al. (2021) Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. Asia-Pacific Journal of Clinical Oncology 18: 201-208. DOI: 10.1111/ajco.13576
Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, et al (2022) Real-world outcomes of Ribociclib and Aromatase inhibitor use in first line hormone receptor positive , HER2-negative metastatic breast cancer. Clinical Breast Cancer 22, 792-800. DOI: 10.1016/j.clbc.2022.08.011
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, et al. (2022) First-line Nivolumab plus Ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, Phase 3 CheckMate 227 Part 1 trial. Journal of Thoracic Oncology 17, 289-308. DOI: 10.1016/j.jtho.2021.09.010.
Nowak AK, Newton RU, Cruickshank T, Cormie P, Halkett GK, Tsoi D, Galvao DA. (2023) A feasibility, safety, and efficacy evaluation of supervised aerobic and resistance exercise for patients with glioblastoma undertaking adjuvant chemoradiotherapy. Neuro-Oncology Practice 10 (Suppl. 3). DOI: 10.1093/nop/npad006
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, et al. (2023) A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus. Future Oncology 19: 739-752. DOI: 10.2217/fon-2022-1149.
Tripathy D, Tolaney SM Seidman AD et al (2022) Treatment with Etirinotecan Pegol for patients with metastatic breast cancer and brain metastases. JAMA Oncology 8: 1047-1052. DOI:10.1001/jamaoncol.2022.0514 (A/Prof D Tsoi contributing investigator)

St John of God Murdoch Hospital